1. Toxic proteins application in cancer therapy
- Author
-
Zahra Setayesh-Mehr and Mahdiye Poorsargol
- Subjects
0301 basic medicine ,Drug ,Trichosanthin ,media_common.quotation_subject ,Scorpion Venoms ,Bioinformatics ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Genetics ,Medicine ,Animals ,Humans ,Gelonin ,Molecular Biology ,media_common ,business.industry ,Ribosome-inactivating protein ,Cancer ,Translation (biology) ,General Medicine ,Transfection ,medicine.disease ,Antineoplastic Agents, Phytogenic ,030104 developmental biology ,030220 oncology & carcinogenesis ,Drug delivery ,Ribosome Inactivating Proteins, Type 1 ,business ,Sodium Channel Blockers - Abstract
Ribosome inactivating proteins (RIPs) as family of anti-cancer drugs recently received much attention due to their interesting anti-cancer mechanism. In spite of small drugs, RIPs use the large-size effect (LSE) to prevent the efflux process governed by drug resistance transporters (DRTs) which prevents inside of the cells against drug transfection. There are many clinical translation obstacles that severely restrict their applications especially their delivery approach to the tumor cells. As the main goal of this review, we will focus on trichosanthin (TCS) and gelonin (Gel) and other types, especially scorpion venom-derived RIPs to clarify that they are struggling with what types of bio-barriers and these challenges could be solved in cancer therapy science. Then, we will try to highlight recent state-of-the-arts in delivery of RIPs for cancer therapy.
- Published
- 2021